Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma

Research output: Contribution to journal › Comment/debate

Access to Document

@article{4235883ad1c44963a4391fcbeadfc321,

title = "Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma",

author = "Ahmed Kaseb and Pawlik, \{Timothy M.\}",

year = "2025",

month = nov,

day = "1",

doi = "10.1016/S0140-6736(25)02104-X",

language = "Undefined/Unknown",

volume = "406",

pages = "2035--2038",

journal = "The Lancet",

issn = "0140-6736",

number = "10515",

}

TY - JOUR

T1 - Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma

AU - Kaseb, Ahmed

AU - Pawlik, Timothy M.

PY - 2025/11/1

Y1 - 2025/11/1

UR - https://www.scopus.com/pages/publications/105020686507

U2 - 10.1016/S0140-6736(25)02104-X

DO - 10.1016/S0140-6736(25)02104-X

M3 - Comment/debate

C2 - 41125108

AN - SCOPUS:105020686507

SN - 0140-6736

VL - 406

SP - 2035

EP - 2038

JO - The Lancet

JF - The Lancet

IS - 10515

ER -